Man please stop your optimistic what if pie in the sky scenarios.
This is a broke OTC that is unable to execute and provide any timelines. This will be lucky to hold this current market cap given its inability to generate any revenue and its continous dilution and not a single cent to its bank account. Its more likely to go broke than to r4ach any of those valuations. You need sales and/or additiona indications and trials to even sniff grester than $1 share price now. Too much what if here and not enough execution.
Too many really big longs know the worth of this platform technology that is the safest path forward to a cure for all cancers known to date. Safety trumps price longer term so unless something comes along that is both as safe as effective and cheaper DCVax will stay out front. That will take a while to implement too which means an allogenic off the shelf preventative vaccine will have time to be developed from the proteomics work being done. Post L (UCLA) or eventually Direct (NWBO) treatment activated T-Cells will be and are being selected for primary importance with regard to development of an allogenic preventative vaccine. Care to imagine what a worldwide vaccination program against cancer and then other diseases might look like?; ). Best wishes.
Market Data 
Markets 
AI
